CXCL12 and acute myeloid leukemia: In 2021, a phase III clinical trial on acute myeloid leukemia (AML) patients showed promising responses when the CXCL12 chemokines were inhibited by DSTAT (dociparstat sodium) in combination with chemotherapy [123].